Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6556 to 6570 of 8314 results

  1. Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

    This guidance has been updated and replaced by NICE technology appraisal guidance 946.

    Technology appraisal guidance
    Published
    28 April 2021

  2. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    This guidance has been updated and replaced by NICE technology appraisal guidance 836.

    Technology appraisal guidance
    Published
    15 January 2020

  3. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Technology appraisal guidance
    Published
    15 January 2020

  4. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Technology appraisal guidance
    Published
    22 January 2020

  5. Newer drugs for epilepsy in children (TA79)

    This guideline has been updated and replaced by NICE guideline CG137.

    Technology appraisal guidance
    Published
    28 April 2004

  6. Implantable cardioverter defibrillators for arrhythmias (TA95)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Technology appraisal guidance
    Published
    25 January 2006

  7. Computerised cognitive behaviour therapy for depression and anxiety (TA97)

    The guidance was withdrawn in July 2018 to allow OCFighter to be considered for an improving access to psychological therapies assessment briefing. If OCFighter is not selected, it may be considered for a medtech innovation briefing.

    Technology appraisal guidance
    Published
    22 February 2006

  8. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

    This guidance has been updated and replaced by NICE guideline NG87.

    Technology appraisal guidance
    Published
    22 March 2006

  9. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Technology appraisal guidance
    Published
    27 January 2016

  10. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)

    This guidance has been updated and replaced by NICE technology appraisal guidance 412.

    Technology appraisal guidance
    Published
    27 January 2016

  11. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10. 

    Technology appraisal guidance
    Published
    27 March 2002

  12. Apremilast for treating moderate to severe plaque psoriasis (TA368)

    Technology appraisal guidance
    Published
    25 November 2015

  13. The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma (TA37)

    This guidance has been updated and replaced by NICE technology appraisal guidance 137.

    Technology appraisal guidance
    Published
    27 March 2002

  14. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Technology appraisal guidance
    Published
    27 March 2002

  15. Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)

    This guidance has been updated and replaced by NICE technology appraisal guidance 476.

    Technology appraisal guidance
    Published
    28 October 2015